CSL Limited (ASX:CSL) Stock Ends Week Down 7.4% as HEMGENIX Progress Faces Scale Test

The latest verified close was A$114.22 on 24 July, down 1.3%. Australian Securities Exchange CSL lost 7.4% over the week, while the ASX 200 slipped 0.3%. MarketScreener The stock sits 58.6% below its A$275.79 52-week high. Australian Securities Exchange No market-sensitive CSL announcement appeared during that week. CSL Limited The exact catalyst is uncertain.

CSL reports FY26 results on 18 August at 10:00 a.m. AEST. CSL Limited Current guidance is US$15.2 billion revenue and US$3.1 billion NPATA. Both measures use constant currency. NPATA excludes restructuring and impairment charges. Against FY25, they imply declines near 2.6% and 6.1%. CSL will also update impairments and announce the final dividend.

H1 NPATA was US$1.923 billion at constant currency. CSL therefore needs about US$1.177 billion during the second half. A lower second half is normal because Seqirus is seasonally weighted. May guidance already included about US$650 million of specified revenue headwinds. Delivery now depends heavily on Behring growth and cost execution.

CSL expects about US$5 billion of additional pre-tax impairments across FY26 and FY27. Those charges are non-cash and are additional to H1 impairments. H1 restructuring and impairment expense totalled US$2.06 billion before tax. The additional review includes Vifor intangibles and underused fixed assets. Timing and allocation remain subject to audit and board approval. The charges reduce statutory profit and equity, but do not directly consume cash.

Underlying US immunoglobulin demand is still growing at mid-to-high single digits. Yet channel inventory normalisation is reducing FY26 revenue by about US$300 million. H1 immunoglobulin revenue fell 6% to US$3.046 billion. It was still 3% higher than the preceding half. The data suggest demand remains healthier than reported sales. Investors need proof that the inventory reset is nearly finished.

EMA’s medicines committee recommended revoking Tavneos approval in Europe. A European Commission decision is still pending. European Medicines Agency (EMA) CSL expects around US$145 million of FY26 Tavneos revenue. Amgen submitted new FDA analyses on 23 July. Its Week-52 sustained-remission difference was 9.8 percentage points. The 95% confidence interval ran from minus 0.3 to 19.9. Amgen The FDA has not ruled, and no decision date is set. U.S. Food and Drug Administration

CSL no longer targets completing the Seqirus demerger during FY26. Management says separation remains preferred, but timing depends on vaccine-market conditions. In May, operational separation inside CSL was on track for 1 July. H1 Seqirus revenue fell 2% to US$1.646 billion. Seasonal influenza sales rose 1%, despite a projected 6%–8% US market decline. No new demerger date has been announced.

Gordon Naylor remains CSL’s interim chief executive. In May, CSL said its global search was progressing as planned. The company gave no appointment date. CSL expects Naylor to remain a non-executive director after the transition. No later company announcement has named a permanent successor. CSL Limited

The US$750 million buyback ended on 5 May. CSL purchased 6.407 million shares for A$1.065 billion. The average purchase price was about A$166.16. The latest close sits 31.3% below that average. Those shares equalled about 1.3% of the starting count. CSL Limited H1 leverage reached the 2.0-times ceiling of management’s target range. The interim dividend remained US$1.30 per share.

The latest 16-analyst snapshot shows an average target of A$138.93. That is about 21.6% above the latest verified close. Seven rate CSL a buy, nine say hold, and none sell. The target range runs from A$103.73 to A$198.71. Investing.com Morgan Stanley retained Overweight and cut its target to A$163 on 22 July. FNArena.com Broker targets vary widely. They may also lag new disclosures.